August 18, 2021 5:38pm

Biostage (BSTG) Chronicles: Slips on management reviews (-$0.10) after Tuesday’s flat and Monday’s (-$0.22); is the end coming …

Pre-open indications: 5 MISS and 4 HITs

My comments try to distinguish the temporary from real pricing digression or progress.

Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?

The Dow closed DOWN -382.59 points (-1.09%); the S&P closed DOWN -47.81 points (-1.07%) while the Nasdaq closed DOWN -130.27 points (-0.89%)

 

Henry’omics:

Indexes slipped to the downside …

As stocks traded sideways on Wednesday, investors had just experienced weaker-than-expected economic data and mixed retail earnings results.

The S&P 500 dropped -0.7% during the trading day on Tuesday to end a five-session winning streak and post its biggest decline in a month.The Dow fell -1.1%, the S&P 500 dipped -1.1%; the two averages both snapped five-day winning streaks in the prior session while the Nasdaq edged roughly -0.9%.

Stocks were rocked as the Federal Open Market Committee's (FOMC) published its meeting minutes from its July gathering, revealing discussions about possibly dialing back its monthly bond-buying program this year.

  • The minutes of the July 27-28 Fed meeting showed different groups worried about inflation and the need to prepare to combat it, with others saying it would take time, and require patience from the Fed, to put Americans back to work. <Reuters>

 

RegMed Investors’ (RMi) pre-open: “there are no easy targets as indications follow casino rules. Just remember it’s a “fishing game” enabling the number of variations. A “witching: option expiration on Friday.” … https://www.regmedinvestors.com/articles/12054

 

The Biostage (BSTG) Chronicles: “Facts from filed 10-Q” … https://www.regmedinvestors.com/articles/12055

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 23

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Wednesday opened negative at 7/26, 1 flat and 1 acquired, flipped positive at the mid-day to 20/9, 1 flat and 1 acquired, then flipped to a negative close of 9/24, 1 flat and 1 acquired;

 

Key Metrics:

  • Sector volume was LOW with 3 of the 9-upside having higher than the 3-month average volume with very LOW volume of 1 of 24-downside having higher than the 3-month average volume;
  • Wednesday’s percentage (%) of the 9-upside were +0.36% (BLCM) to +7.77% (FATE) while the 24-downside -0.16% (BLFS) to -7.60% (RARE);

 

The Biostage (BSTG) Chronicles: Wednesday closed down -$0.10 with 739 shares traded after Tuesday closed flat with 1 share traded after Monday closed down -$0.22 to $1.38 with 135 shares traded, Friday closed flat again with 10 shares traded, Thursday closed flat with 50 shares traded after last Wednesday with 50 shares traded.

  • Notice, how the share trades without and with the “push/promote” – today is just another typical example;
  • Read the recently issues 10-Q and 8-K which will magnify the “incompetence” of the current management team, the BOD and their “advisors” … The Biostage (BSTG) Chronicles: Facts from filed 10-Q … https://www.regmedinvestors.com/articles/12055

 

Pre-open Indications: 4 HITs <Maintaining SELL: Biostage (BSTG -$0.00); Cellectis SA (CLLS +$0.28), Pluristem (PSTI +$0.09), Vericel (VCEL -$0.44)> 5 MISS < BUY: CRISPR Therapeutics (CRSP -$1.23), Editas Medicine (EDIT -$1.12), Intellia Therapeutics (NTLA -$1.02), Sangamo Therapeutics (SGMO -$0.27), Verastem (VSTM -$0.07) >

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Fate Therapeutics (FATE), Chinook Therapeutics (KDNY), Regenxbio (RGNX), Cellectis SA (CLLS), MiMedx (MDXG) to name 5 of the 9 inclining of the 35 covered

Hammered in today’s market:

  • Ultragenyx (RARE), ReNeuron (RENE.L), Alnylam Pharmaceuticals (ALNY), uniQure NV (QUR), Global Blood Therapeutics (GBT) to name 5 of the 24 declining of the 35 covered

 

Wednesday’s (9 of 9) incliners:

  • Fate Therapeutics (FATE +$6.56 after Tuesday’s -$3.19 and Monday’s +$0.92);
  • Chinook Therapeutics (KDNY +$0.49 after Tuesday’s -$0.94);
  • Regenxbio (RGNX +$0.34 after Tuesday’s +$0.42);
  • Cellectis SA (CLLS +$0.28 after Tuesday’s -$0.26 and Monday’s +$0.07);
  • MiMedx (MDXG +$0.11);
  • Pluristem (PSTI +$0.09 after Tuesday’s -$0.22);
  • Voyager therapeutics (VYGR +$0.06);
  • Caladrius Biosciences (CLBS +$0.01 after Tuesday’s -$0.01);
  • Bellicum Pharmaceuticals (BLCM+$0.01 after Tuesday’s -$0.10);

Wednesday’s (10 of 24) decliners:

  • Ultragenyx (RARE -$6.74 after Tuesday’s +$0.70 and Monday’s -$4.74);
  • ReNeuron (RENE.L -$3.50 after Tuesday’s +$1.00 and Monday’s flat);
  • Alnylam Pharmaceuticals (ALNY -$3.47 after Monday’s +$0.24);
  • uniQure NV (QURE -$1.34 after Tuesday’s +$0.47 and Monday’s -$0.61);
  • Global Blood Therapeutics (GBT -$1.29 after Tuesday’s +$0.96 and Monday’s -$0.83);
  • CRISPR Therapeutics (CRSP -$1.23 after Tuesday’s +$2.00 and Monday’s -$4.21);
  • Editas Medicine (EDIT -$1.12 after Tuesday’s +$1.10 and Monday’s -$2.66);
  • Intellia Therapeutics (NTLA -$1.02 after Tuesday’s +$0.80 and Monday’s -$2.74);
  • Ionis Pharmaceuticals (IONS -$0.73);
  • Sage therapeutics (SAGE -$0.67);

Closing – 1 – Solid Biosciences (SLDB), and 1 -Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed down -1.39% and XBI closed down -1.69%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was up +3.36 points or +20.44% at 21.57

Upside volume:

  • Wednesday:  3 out of the 9-upside had higher than the 3-month average volume;

Downside volume:

  • Wednesday: 1 out of the 25-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

  • Wednesday’s percentage (%) of the 9-upside were +0.36% (BLCM) to +7.77% (FATE) while the 24-downside -0.16% (BLFS) to -7.60% (RARE);

August, the second month of Q3/21:

  • Wednesday closed negative with 9 advancers, 24 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: Another trip and a fall but, the sector is being oversold is the ability to be overbought after multiple sessions.

Sector Q2 earnings (26) contributed to the declining slope of many equities; so far released have been weak (3 net incomes and 23 net losses) and as usual, investors are worried that the clinical advances are in-short supply.

As I had stated, “the cell and gene therapy sector will be driven driven by two things: 1) earnings, 2) news and 3) multiples.”

There have been jitters and negativity whispers about earnings releases’ and I think some underlying worries re sector share pricings yet, a rally surprised many today.

A tool that hasn’t resonated … guidance is one factor of the sector.

I am keeping an eye on “runways” … as 2024 seems to be timing factor for most.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.